Fukasawa Kanon, Higashimoto Yuichiro, Motomiya Yoshihiro, Uji Yoshinori, Ando Yukio
Department of Chemistry, Kurume University School of Medicine, Kurume, Fukuoka, Japan.
Suiyukai Clinic, Kashihara, Nara, Japan.
Mol Biol Res Commun. 2016 Dec;5(4):225-232.
Dialysis-related amyloidosis (DRA) is characterized by accumulation of amyloid β2- microglobulin (β2m) in the interstitial matrix. Matrix substances such as heparin have reportedly been strongly implicated in the pathogenesis of dialysis-related amyloidosis. In clinical setting of hemodialysis, two types of heparin, i.e., high and low molecular heparin (H.M.H. and L.M.H.) have been routinely used. Still commonly used is H.M.H., followed by L.M.H. preparations with distinct advantages. Here, we studied that the interaction of native and two amyloidogenic β2m variants: ΔN6β2m and D76N β2m with H.M.H. and L.M.H. We also investigated whether heparin could induce β2m to have an amyloidogenic conformation. Biolayer interferometry revealed that ΔN6β2m had a strong reaction and D76N β2m had a moderate reaction with H.M.H.. Furthermore,H.M.H. induced the C-terminal unfolding in a native β2m. By contrast, L.M.H. showed no reaction even with ΔN6β2m. This study showed firstly a direct binding of β2m with H.M.H.. H.M.H. would provoked a C-terminal unfolding of β2m, which indicated production of an amyloidogenic intermediate, i.e., β2m92-99. In addition, our findings also suggest that L.M.H. may provide beneficial effects against the development of the DRA.
透析相关淀粉样变(DRA)的特征是淀粉样β2-微球蛋白(β2m)在间质基质中蓄积。据报道,诸如肝素等基质物质与透析相关淀粉样变的发病机制密切相关。在血液透析的临床环境中,常规使用两种类型的肝素,即高分子肝素和低分子肝素(H.M.H.和L.M.H.)。目前仍常用H.M.H.,其次是具有明显优势的L.M.H.制剂。在此,我们研究了天然型和两种淀粉样变β2m变体:ΔN6β2m和D76N β2m与H.M.H.和L.M.H.的相互作用。我们还研究了肝素是否能诱导β2m形成淀粉样变构象。生物层干涉术显示,ΔN6β2m与H.M.H.反应强烈,D76N β2m与H.M.H.反应中等。此外,H.M.H.诱导天然β2m的C末端展开。相比之下,L.M.H.即使与ΔN6β2m也无反应。本研究首次表明β2m与H.M.H.直接结合。H.M.H.会引发β2m的C末端展开,这表明产生了淀粉样变中间体,即β2m92-99。此外,我们的研究结果还表明,L.M.H.可能对DRA的发展具有有益作用。